Observational Cohort Study of Advanced Non-small Cell Lung Cancer (CAPTRA-LUNG)

Peking Union Medical College Hospital5,000 enrolled

Overview

Investigators propose to establish and maintain a cohort of patients with advanced non-small cell lung cancer, and to assess the treatment pattern, host genetic, and clinical factors which influence the prognosis and survival, as well as the interaction among these factors on disease diagnosis and treatment, short and long-term outcomes. Study type: Observational (Patient Registry) Study design: Observational Model: Cohort Time Perspective: Prospective and retrospective

Study Type

OBSERVATIONAL

Enrollment

5,000

Conditions

Advanced Non-small Cell Lung Cancer

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Cohort I: diagnosis of advanced non-small cell lung cancer from 2012-2016; * Cohort II: documented positive driver gene mutations; and diagnosis of advanced non-small cell lung cancer; * Cohort III: diagnosis of advanced non-small cell lung cancer and in immune-therapy; * Cohort IV: diagnosis of advanced non-small cell lung cancer, and with wild-type driver gene or unknown driver gene status; * Cohort V: treated with anti-VEGF drug in first line, diagnosis of advanced non-squamous and non-small cell lung cancer in 6 months before recruit; * Age\>18 years; * Provision of written informed consent. Exclusion Criteria: * not applicable

Locations (1)

Peking Union Medical College Hospital

Beijing, Beijing Municipality, China

RECRUITING

Outcomes

Primary Outcomes

Overall Survival (OS)

OS was calculated from the diagnosis of advanced non-small cell lung cancer to death from any reasons

Time frame: 3 years

Central Contacts

Yan Xu, M.D.

CONTACT

861069155039 maraxu@163.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.